/PRNewswire/ Deciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional.
/PRNewswire/ Deciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional.
SAN FRANCISCO, Oct. 27, 2021 /PRNewswire/ Deciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional Scientific.
E-Mail
Scientists at UC San Francisco are learning how immune cells naturally clear the body of defunct - or senescent - cells that contribute to aging and many chronic diseases. Understanding this process may open new ways of treating age-related chronic diseases with immunotherapy.
In a healthy state, these immune cells - known as invariant Natural Killer T (iNKT) cells - function as a surveillance system, eliminating cells the body senses as foreign, including senescent cells, which have irreparable DNA damage. But the iNKT cells become less active with age and other factors like obesity that contribute to chronic disease.